By Fineline Cube 
EClinCloud (Ningbo) Technology Co., Ltd., a leading AI technology company specializing in clinical research solutions, has announced the completion of a new round of financing worth tens of millions of yuan. The investment was exclusively led by Hongfeng, a renowned biopharmaceutical investment firm. This funding will further accelerate EClinCloud’s deep research and innovation in AI technology, while supporting the company’s global strategic expansion, bringing stronger digital momentum to new drug development and medical device clinical research.
Company Overview
EClinCloud is dedicated to providing efficient and precise digital solutions for global pharmaceutical companies and research institutions through its intelligent integrated cloud platform and AI-driven clinical endpoint evaluation technology. The company offers a range of technology products and services including eCOA, CTMS, eTMF, EDC, RTSM, IRC, and RM, as well as scale management, linguistic validation, rater training, and data quality analysis. By leveraging AI predictive models and intelligent data platforms, EClinCloud dynamically assesses and enhances the success rate of clinical trials, helping to shorten the development cycle for drugs and medical devices, ultimately benefiting patients.
Leadership and Expertise
The core founding team of EClinCloud brings over 15 years of experience in new drug development, supported by impressive academic backgrounds. The team includes:
- CEO Michael Qin, a Ph.D. in Management from Beihang University and a postdoctoral researcher in Medical Statistics at Sun Yat-sen University.
- CTO Weiping Wu, a Bachelor’s degree in Computer Science and Technology from Tsinghua University and a Master’s degree in Economics from Peking University.
- CBDO Quanyu Su, a Master’s degree in Business Administration from Peking University and the University of Northwestern, USA.
- Medical Operations Director Zhiwei Zhang, a Master’s degree in Immunology from Peking University.
Company Background
Established on February 18, 2020, EClinCloud has Michael Qin as its legal representative and a registered capital of 5 million yuan. The company’s business scope includes medical software development, data processing and storage services, and medical information technology consulting. Through equity pierce through, it is revealed that Long Qin is the actual controller with a total shareholding ratio of 57.06%.-Fineline Info & Tech